Testimony before the

House Committee on Energy and Commerce

Subcommittee on Oversight and Investigations

Anthony S. Fauci, M.D.

Director of the National Institute of Allergy and Infectious Diseases

March 8, 2018
Mr. Chairman, Ranking Member DeGette, and members of the Subcommittee, thank you for the opportunity to discuss the response of the National Institutes of Health (NIH) to the public health threat posed by influenza. I direct the National Institute of Allergy and Infectious Diseases (NIAID), the lead NIH institute for conducting and supporting research on established and emerging infectious diseases, including influenza.

NIAID funds a longstanding, comprehensive portfolio of basic, translational, and clinical research on influenza focused on better understanding the virus and the disease that it causes as well as developing diagnostics, therapeutics, and vaccines to prevent and treat it. The current, remarkably severe influenza season, the consistently changing nature of seasonal influenza viruses, together with the ever-present threat of pandemic influenza, underscore the importance of this research to improve on our current influenza vaccines, as well as to lead us on a pathway toward the development of a universal influenza vaccine. The latter would provide long-lasting protection against multiple seasonal and pandemic influenza viruses. NIAID efforts in this regard are bolstered by ongoing collaborations with academia, philanthropic organizations, biotechnology and pharmaceutical companies, as well as U.S. government partners, particularly the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the Office of the Assistant Secretary for Preparedness and Response (ASPR), including the Biomedical Advanced Research and Development Authority (BARDA).

**Fundamental Research to Understand Influenza Evolution and Immunity**
NIAID-supported basic research on influenza provides the foundation for developing new and improved diagnostics, antiviral therapies, and vaccines for influenza caused by both seasonal and pandemic virus strains. Detailed studies of how our immune system responds to influenza viruses and influenza vaccines are stimulating novel approaches for developing vaccine candidates that can elicit robust immune responses and provide broad protection against a variety of influenza virus strains. In accordance with the highest bioethical and scientific standards, NIH clinical researchers are investigating human influenza infection under carefully controlled conditions in which healthy volunteers are challenged with influenza virus. The scientists are closely examining the course of influenza infection from the moment of exposure to the virus to determine when viral shedding occurs, when symptoms begin and end, and when the body begins to mount an immune response against the virus. The researchers also are studying factors correlated with protection against influenza. These influenza challenge studies will serve as an efficient way to evaluate the safety and efficacy of novel approaches to treat or prevent influenza infection. The findings from these studies already are informing the design of future clinical trials to evaluate candidate influenza countermeasures, including vaccines. Additionally, NIAID is soliciting research proposals for studies that will follow cohorts of infants to determine how natural influenza infections and/or influenza vaccinations shape their responses to future influenza virus exposures as they enter adolescence and adulthood. The ultimate goal of this research is to provide key information to facilitate the design of broadly and durably protective influenza vaccines.

NIAID also supports research to better understand the transmission, evolution, and pathogenesis of influenza viruses in animals and humans to inform the development of broadly protective influenza vaccines. For example, the NIAID Centers of Excellence for Influenza Research and
Surveillance (CEIRS) study the emergence and spread of novel influenza viruses worldwide to lay the groundwork for new and improved control measures for circulating influenza viruses. The CEIRS global network of research sites has characterized newly detected influenza virus strains and has evaluated potential vaccine approaches for emerging influenza viruses, including those of avian origin. CEIRS investigators also have recapitulated influenza virus evolution in the laboratory, allowing them to predict viral mutations that may occur in nature. This information can be used to help design seasonal influenza vaccines that optimally match circulating strains. Influenza virus surveillance programs using next-generation genomic technologies supported by NIH also are providing an in-depth view of influenza virus evolution and insights into reducing the disease burden of seasonal and pandemic influenza.

**Influenza Vaccines**

*Challenges Presented by Current Influenza Vaccines*

Licensed annual influenza vaccines, the primary tool for prevention of seasonal influenza, are updated each year to address the strains that experts deem likely to circulate during the upcoming influenza season. These vaccines are updated annually through supplements to their FDA licenses, which must be approved by FDA prior to distribution of the vaccines. The overall efficacy of seasonal influenza vaccines ranges from 40 to 60 percent when there is a good match between the vaccine and circulating influenza viruses, although they may be significantly less effective when varying degrees of mismatches occur between the circulating strains and the vaccine. These mismatches can be caused by the constant evolution of circulating influenza strains, as was observed in the 2014-2015 influenza season, or by mutations that occur when
viruses from humans are adapted to grow in eggs, a requirement for the egg-based vaccine manufacturing process, the predominant technology used for influenza vaccines globally.

The public health response to influenza becomes particularly challenging when a pandemic strain emerges. This happens when the vast majority of the population has not been exposed to a newly emerging influenza strain and lacks immunity to it, as occurred with the 2009 pandemic H1N1 influenza virus. The less than optimal efficacy of vaccines against seasonal influenza together with the constant threat that a pandemic strain may emerge, and the risk of seasonal influenza vaccine mismatches, emphasize the need for additional strategies to address both seasonal and pandemic influenza. A more broadly protective, or universal, influenza vaccine would be a valuable tool in our efforts to generate more durable protection against multiple influenza strains. It would also be important as we are pursuing the development of a universal influenza vaccine to improve on the efficacy of our current vaccines since it will take several years to develop a universal influenza vaccine ready for widespread use.

Universal Influenza Vaccines

NIAID has made the development of universal influenza vaccines a high priority, and in this regard, has begun a concerted effort to galvanize research in the field. On June 28-29, 2017, NIAID convened a group of domestic and international influenza experts at a research agenda-setting workshop, “Pathway to a Universal Influenza Vaccine.” Following this meeting, NIAID outlined its research priorities in a Strategic Plan for a Universal Influenza Vaccine published online on February 28, 2018, by the Journal of Infectious Diseases. The Strategic Plan focuses on three research areas: improving knowledge of the transmission, natural history, and pathogenesis of influenza infection; characterizing influenza immunity and immune factors that
correlate with protection against influenza; and supporting the rational design of universal influenza vaccines. Targeted investments in each of these research areas will be required to generate the critical information necessary to enable the development of universal vaccines effective against both seasonal and pandemic influenza.

*Strategies for Universal Influenza Vaccines*

Current NIAID research on universal influenza vaccines pursues multiple strategies that target parts of the influenza virus common across multiple influenza strains in an effort to broaden the immune system response and cover multiple, diverse influenza viruses. One scientific challenge in developing a truly universal vaccine relates to the influenza surface protein hemagglutinin (HA). Most antibodies against influenza virus target the “head” of the mushroom-shaped HA protein, which differs from strain to strain of influenza viruses and is constantly changing by mutation. In contrast, the “stem” of the mushroom-shaped HA protein remains relatively constant among diverse influenza virus strains, suggesting that strategies to generate immune responses against the HA stem could elicit broader protection against multiple influenza virus strains.

Scientists at the NIAID Vaccine Research Center (VRC) have developed a vaccine candidate consisting of a ferritin nanoparticle to which is attached multiple copies of the stabilized headless stem of the HA protein from an H1N1 influenza virus. This vaccine more effectively elicits an immune response specifically against the stem and protected animals against lethal influenza infection. Notably, the vaccine protected against a different influenza subtype (H5) than the H1 subtype upon which it was based, providing a proof-of-concept that vaccines targeting the HA stem could offer broad protection against diverse influenza strains.
In addition, VRC researchers have conducted several clinical trials of another influenza vaccine strategy designed to elicit enhanced and broadly reactive antibody responses. Recent NIAID Phase I clinical trials have tested an initial vaccination with an influenza virus DNA vaccine candidate known as a “prime” followed by a “boost” with a standard inactivated seasonal influenza vaccine. The clinical trials demonstrated that such regimens were safe and produced anti-influenza A immune responses. NIAID intramural scientists also are evaluating a universal influenza vaccine consisting of a cocktail of avian influenza viruses comprised of either virus-like particles or inactivated vaccine strains. Both vaccine regimens protected mice and ferrets from infection with a wide range of influenza A strains, including strains not contained in the vaccine, suggesting another potential strategy to develop a universal influenza vaccine. NIAID plans to conduct Phase I safety and immunogenicity studies of this vaccine approach by next year. NIAID continues to evaluate each of these vaccine strategies to better understand how they could contribute to the design of universal influenza vaccines.

NIAID also is pursuing novel vaccine approaches that may induce or boost broadly protective immune responses by targeting other conserved influenza proteins such as the nucleoprotein (NP) and the ion channel matrix protein (M2). In addition, NIAID is planning a Phase II clinical trial of M-001, a vaccine candidate that contains several influenza fragments recognized by the immune system that are common among multiple influenza virus strains. The trial will assess whether receiving M-001 as a prime can help generate enhanced immune responses to a boost vaccination with a licensed seasonal influenza vaccine.

A truly universal influenza vaccine would represent a groundbreaking advance in the fight against influenza. Although we cannot predict when a more broadly protective influenza vaccine
would be publicly available, we expect that progress toward that goal will occur in iterative and progressive steps. NIAID-supported research already has produced promising results. However, we anticipate that it will require significant scientific effort, and multiple refinements along the way, to achieve long-lasting, broadly protective vaccines that can be used in all populations. As we develop such vaccines, promising candidates will need to be evaluated over several influenza seasons to determine the extent and durability of the protection that they induce.

*Improving Current Influenza Vaccines*

Concurrent with efforts to develop a universal influenza vaccine, NIAID supports the development of flexible vaccine manufacturing processes, including the use of molecular biological techniques, to help shorten manufacturing times and increase production efficiency for current and future influenza vaccines. NIAID and industry partners are investigating recombinant DNA manufacturing techniques that could be rapidly mobilized when pandemic viruses emerge. In addition, NIAID has supported studies of improved vaccine strain selection and optimized high-yield vaccine strains as part of the Seasonal Influenza Vaccine Improvement (SIVI) initiative, an interagency collaboration launched in 2016. The SIVI initiative builds upon the success of the Influenza Vaccine Manufacturing Improvement (IVMI) initiative, a collaboration with ASPR/BARDA, CDC, FDA, and vaccine manufacturers. The SIVI initiative focuses on approaches to maintain the effectiveness of seasonal influenza vaccines in years when circulating viral strains have drifted by mutating.

In addition, NIAID has supported the development of a new test that can be used to measure the amount of antigen – the substance that generates an immune response – in vaccines to enable a rapid vaccine response during an influenza outbreak or pandemic. The VaxArray Influenza
Pandemic Hemagglutinin test is a new immunoassay for seasonal and pandemic influenza vaccines that can identify multiple HA subtypes, including H5, H7, and H9. This assay represents an improvement over current tests because it can be deployed rapidly to determine and monitor the potency of a greater number of vaccine formulations, such as adjuvanted vaccines and dose-sparing vaccine preparations.

Pandemic Vaccine Approaches

For decades, NIAID has supported research to prepare for the possible emergence of pandemic influenza. NIAID, in collaboration with BARDA, has evaluated candidate vaccines against pandemic influenza viruses such as the 2009 H1N1 and potential pandemic influenza viruses including H5N1 and H7N9. In the last five years, NIAID has supported 10 clinical trials enrolling more than 3,000 volunteers to assess the safety and immunogenicity of candidate pandemic influenza vaccines. These trials were conducted through the NIAID Vaccine and Treatment Evaluation Units (VTEUs), a longstanding clinical trials network for rapid testing of candidate vaccines and therapeutics. Several of the vaccines also were evaluated for use in special populations such as children and older adults. The VTEUs currently are conducting two Phase II clinical trials of a new vaccine to protect against emerging H7N9 influenza virus strains. The trials are now enrolling volunteers at sites across the United States to test the vaccine’s immunogenicity and safety at different dosages and treatment schedules. The studies also will evaluate whether a product called an adjuvant given together with the vaccine boosts the immune response of people receiving the vaccine. In addition, NIAID intramural scientists are conducting clinical studies of prime-boost vaccine regimens for swine (H1) and avian (H7) influenza
viruses, and collaborating with industry and BARDA to develop live, attenuated vaccines against influenza viruses with pandemic potential.

**Influenza Diagnostics**

NIAID supports the development of influenza diagnostics with improved speed, accuracy, and usability in settings where patients seek medical care. NIAID is helping to develop molecular diagnostic platforms capable of quickly distinguishing between seasonal strains. For example, a rapid molecular test system developed with longstanding NIAID support was recently cleared by the FDA to accurately distinguish influenza A from influenza B in nasal swab specimens. NIAID also supports the development of clinical assays to determine whether influenza virus strains are sensitive to neuraminidase inhibitors – drugs such as Tamiflu that can lessen the duration and severity of illness as well as potentially prevent infection in close contacts.

**Antiviral Therapies for Influenza**

Antiviral therapies for influenza are important tools in treating and preventing complications of influenza infection. However, the emergence of resistance to existing antiviral medications highlights the need for additional treatment options. NIAID supports research to develop broad-spectrum antiviral drugs and other novel influenza therapeutics, several of which have advanced to clinical trials. For example, NIAID has furthered the development of RNA polymerase inhibitors, peptide inhibitors, and next-generation neuraminidase inhibitors. NIAID also is developing monoclonal antibodies against the influenza HA protein, which facilitates the attachment of the virus to respiratory tract cells. Antibodies that bind to HA potentially could block the interaction between the virus and human cells and thus mitigate influenza disease.
Several of these antibodies are currently in Phase II clinical trials, including a novel monoclonal antibody targeting the stem of the influenza HA protein. In addition, NIAID has launched three clinical trials to assess the effectiveness of novel influenza therapeutics in high-risk populations. These therapeutics include human plasma containing high levels of anti-influenza antibodies, concentrated immunoglobulin with high levels of anti-influenza antibodies, and a combination of three licensed influenza antiviral drugs.

**Conclusion**

NIAID has a long history of comprehensive and cutting-edge influenza research to develop better diagnostics, therapeutics, and vaccines. Sustained support of NIAID’s basic, translational, and clinical influenza research will generate the knowledge needed to reach the goal of safe and effective influenza vaccines that provide durable protection against multiple strains of influenza virus and help us prepare for the next potential pandemic. NIAID will continue to collaborate with government, academic, and industry partners to develop improved tools to prevent, diagnose, and treat influenza infection. Importantly, NIAID will use its new Strategic Plan for a Universal Influenza Vaccine to guide future investments in influenza research to accelerate progress toward broadly protective influenza vaccines.